Instructor in Medicine, Harvard Medical School Co-Founder Vasculitis and Glomerulonephritis Center
BiographyDr. Miloslavsky's primary clinical interest is diagnosis and treatment of systemic vasculitis. As part of the vasculitis group, he has worked extensively on a multicenter randomized trial that established rituximab as an important treatment option in ANCA-associated vasculitis (RAVE trial). He is currently involved in several ongoing clinical trials in vasculitis that aim to improve the treatment of these conditions.
Dr. Miloslavsky also has a strong interest in medical education. He currently teaches at MGH and Harvard Medical School where he has received several teaching awards and has published on the role of simulation and peer teaching in medical education.
Miloslavsky EM, Specks U, Merkel PA et al. Rituximab for the treatment of relapses in ANCA-associated vasculitis. Arthritis Rheumatol. 2014 Jul 21.
Miloslavsky E, Unizony S. The heart in vasculitis. Rheum Dis Clin North Am. 2014 Feb;40(1):11-26.
Miloslavsky EM, Specks U, Merkel PA et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013 Sep;65(9):2441-9.
Unizony S, Arias-Urdaneta L, Miloslavsky EM et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012 Nov;64(11):1720-9.